Biochemically-defined pools of amyloid-β in sporadic Alzheimer's disease: Correlation with amyloid PET

Brain

Volumn 140, Issue 5, 2017, Pages 1486-1498

  Roberts, Blaine R ^a   Lind, Monica ^a   Wagen, Aaron Z ^a   Rembach, Alan ^a   Frugier, Tony ^a   Li, Qiao Xin ^a   Ryan, Timothy M ^a   McLean, Catriona A ^a,b   Doecke, James D ^c   Rowe, Christopher C ^a,d   Villemagne, Victor L ^a,d   Masters, Colin L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c CSIRO   (Australia)

^d AUSTIN HEALTH   (Australia)

Author keywords

Alzheimer's disease; amyloid imaging; amyloid ; biomarkers

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAY MATTER; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; LIPID MEMBRANE; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; AMYLOID PLAQUE; CASE CONTROL STUDY; FRONTAL LOBE; METABOLISM; NEUROIMAGING; PATHOLOGY; TIME FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CASE-CONTROL STUDIES; FRONTAL LOBE; GRAY MATTER; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS;

EID: 85019595961     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awx057     Document Type: Article

References (49)

1. Benilova I, Karran E, De Strooper B. The toxic Ab oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012; 15: 349-57.
2. Bilousova T, Miller CA, Poon WW, Vinters HV, Corrada M, Kawas C, et al. Synaptic amyloid-b oligomers precede p-tau and differentiate high pathology control cases. Am J Pathol 2016; 186: 185-98.
3. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 2015; 11: 58-69.
4. Bourgeat P, Chetelat G, Villemagne VL, Fripp J, Raniga P, Pike K, et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurol 2010; 74: 121-7.
5. Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, et al. Proliferation of amyloid-b42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci USA 2013; 110: 9758-63.
6. Elbert DL, Patterson BW, Bateman RJ. Analysis of a compartmental model of amyloid beta production, irreversible loss and exchange in humans. Math Biosci 2015; 261: 48-61.
7. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009; 21: 672-87.
8. Fujiki Y, Hubbard AL, Fowler S, Lazarow PB. Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum. J Cell Biol 1982; 93: 97-102.
9. Haass C, Selkoe DJ. Cellular processing of β-amyloid precursor protein and the genesis of amyloid b-peptide. Cell 1993; 75: 1039-42.
10. Hossain S, Grande M, Ahmadkhanov G, Pramanik A. Binding of the Alzheimer amyloid b-peptide to neuronal cell membranes by fluorescence correlation spectroscopy. Exp Mol Pathol 2007; 82: 169-74.
11. Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N, et al. Cerebrospinal fluid Ab42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol 1999; 45: 504-11.
12. Kandimalla KK, Scott OG, Fulzele S, Davidson MW, Poduslo JF. Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid b protein. PLoS One 2009; 4: e4627.
13. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733-6.
14. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Disc 2011; 10: 698-712.
15. Klafki HW, Wiltfang J, Staufenbiel M. Electrophoretic separation of bA4 peptides (1-40) and (1-42). Anal Biochem 1996; 237: 24-9.
16. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-b in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005; 25: 10598-606.
17. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, et al. Oligomeric amyloid b associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 2009; 106: 4012-17.
18. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Ab1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-53.
19. Lleo A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N, et al. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol 2015; 11: 41-55.
20. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245-9.
21. Matveev SV, Spielmann HP, Metts BM, Chen J, Onono F, Zhu H, et al. A distinct subfraction of Ab is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain. J Neurochem 2014; 131: 356-68.
22. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS amyloid-b in Alzheimer's disease. Science 2010; 330: 1774.
23. McColl G, Roberts BR, Pukala TL, Kenche VB, Roberts CM, Link CD, et al. Utility of an improved model of amyloid-beta (Ab1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease. Mol Neurodegener 2012; 7: 57.
24. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Ab amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860-6.
25. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid b proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000; 57: 100-5.
26. Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, et al. Overlapping profiles of Ab peptides in the Alzheimer's disease and pathological aging brains. Alzheimers Res Ther 2012; 4: 18.
27. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid b-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-7.
28. Näslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, et al. Relative abundance of Alzheimer Ab amyloid peptidee variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 1994; 91: 8378-82.
29. Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-b accumulation earlier than positron emission tomography. Brain 2016; 139: 1226-36.
30. Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol 2015; 78: 439-53.
31. Phan HT, Hata T, Morita M, Yoda T, Hamada T, Vestergaard MC, et al. The effect of oxysterols on the interaction of Alzheimer's amyloid beta with model membranes. Biochim Biophys Acta 2013; 1828: 2487-95.
32. Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H, et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol 2010; 120: 185-93.
33. Rabilloud T, Adessi C, Giraudel A, Lunardi J. Improvement of the solubilization of proteins in two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 1997; 18: 307-16.
34. Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, et al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement 2014a; 10: 53-61.
35. Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, et al. Plasma amyloid-b levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. J Alzheimers Dis 2014b; 40: 95-104.
36. Roberts BR, Ryan TM, Bush AI, Masters CL, Duce JA. The role of metallobiology and amyloid-b peptides in Alzheimer's disease. J Neurochem 2012; 120 (Suppl 1): 149-66.
37. Rowe CC, Villemagne VL. Amyloid imaging with PET in early Alzheimer disease diagnosis. Med Clin North Am 2013; 97: 377-98.
38. Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement 2015; 11: 964-74.
39. Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, et al. Truncated beta-amyloid peptide species in preclinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem 2003; 85: 1581-91.
40. Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, et al. Combination assay of CSF tau, Ab1-40 and Ab1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 1998; 158: 134-40.
41. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid b peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 8098-102.
42. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid b deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12: 357-67.
43. Villemagne VL, Dore V, Yates P, Brown B, Mulligan R, Bourgeat P, et al. En Attendant Centiloid. Adv Res 2014; 2: 723-9.
44. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011; 52: 1210-17.
45. Walsh DM, Teplow DB. Alzheimer's disease and the amyloid b-protein. Prog Mol Biol Transl Sci 2012; 107: 101-24.
46. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Ab distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 1999; 158: 328-37.
47. Wilhelmus MM, de Waal RM, Verbeek MM. Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease. Mol Neurobiol 2007; 35: 203-16.
48. Zhao Q, Liang Y, Yuan H, Sui Z, Wu Q, Liang Z, et al. Biphasic microreactor for efficient membrane protein pretreatment with a combination of formic acid assisted solubilization, on-column pH adjustment, reduction, alkylation, and tryptic digestion. Anal Chem 2013; 85: 8507-12.
49. Zlokovic BV, Martel CL, Mackic JB, Matsubara E, Wisniewski T, McComb JG, et al. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid β. Biochem Biophys Res Commun 1994; 205: 1431-7.